NYSE - Nasdaq Real Time Price • USD
Bristol-Myers Squibb Company (BMY)
As of 3:27 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 21 | 25 |
| Avg. Estimate | 1.7 | 1.65 | 0.52 | 6.96 |
| Low Estimate | 1.54 | 1.55 | -0.1 | 6.27 |
| High Estimate | 2.05 | 1.71 | 0.85 | 7.64 |
| Year Ago EPS | 1.75 | 1.82 | 7.51 | 0.52 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 25 | 25 |
| Avg. Estimate | 11.5B | 11.22B | 45.98B | 46.24B |
| Low Estimate | 11.22B | 11.09B | 45.32B | 42.68B |
| High Estimate | 11.73B | 11.52B | 46.88B | 48.07B |
| Year Ago Sales | -- | 9.99B | 45.01B | 45.98B |
| Sales Growth (year/est) | -- | 12.30% | 2.20% | 0.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.98 | 1.61 | 1.53 | -4.44 |
| EPS Actual | 1.75 | 1.82 | 1.7 | -4.4 |
| Difference | -0.23 | 0.21 | 0.17 | 0.04 |
| Surprise % | -11.60% | 13.00% | 11.10% | 0.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.7 | 1.65 | 0.52 | 6.96 |
| 7 Days Ago | 1.77 | 1.7 | 0.65 | 7.07 |
| 30 Days Ago | 1.77 | 1.73 | 6.83 | 7.1 |
| 60 Days Ago | 1.78 | 1.73 | 6.85 | 7.14 |
| 90 Days Ago | 1.86 | 1.81 | 7.09 | 7.36 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 4 | 3 |
| Up Last 30 Days | 4 | 3 | 5 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 9 | 9 | 8 | 8 |
Growth Estimates
| CURRENCY IN USD | BMY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -2.90% | -- | -- | 1.50% |
| Next Qtr. | -9.30% | -- | -- | 12.10% |
| Current Year | -93.10% | -- | -- | 4.40% |
| Next Year | 1,238.50% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -4.17% | -- | -- | 10.97% |
| Past 5 Years (per annum) | 13.30% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | BMO Capital: Market Perform to Market Perform | 4/26/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 4/26/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 4/18/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 2/6/2024 |
| Downgrade | Redburn Atlantic: Buy to Neutral | 2/6/2024 |
| Downgrade | B of A Securities: Buy to Neutral | 1/3/2024 |
Related Tickers
PFE Pfizer Inc.
25.49
+0.89%
MRK Merck & Co., Inc.
131.16
+0.34%
GILD Gilead Sciences, Inc.
65.61
+0.51%
JNJ Johnson & Johnson
146.45
-0.26%
ABBV AbbVie Inc.
159.91
-4.41%
AZN AstraZeneca PLC
75.31
+0.37%
BIIB Biogen Inc.
210.22
+3.83%
LLY Eli Lilly and Company
733.80
+1.23%
AMGN Amgen Inc.
271.03
+0.61%
SNY Sanofi
49.32
-0.08%